(EVH) Evolent Health - Ratings and Ratios

Evolent Health, Inc. (NYSE:EVH) is a healthcare technology company specializing in value-based care solutions. Through its subsidiary, the firm delivers care management services in high-impact clinical areas such as oncology, cardiology, and musculoskeletal care. Its integrated platform supports health plan administration and value-based infrastructure, enabling providers and payers to transition from fee-for-service to value-based care models. The company offers a suite of administrative services, including health plan management, pharmacy benefits administration, risk management, and advanced analytics. Its proprietary technology, Identifi, aggregates and analyzes data to optimize care workflows and enhance patient engagement. Additionally, Evolent provides total cost of care management and Machinify Auth, an AI-driven software platform designed to improve care delivery and operational efficiency. Founded in 2011, the company is headquartered in Arlington, Virginia, and serves as a key player in the healthcare technology sector.

From a forecasting perspective, EVHs stock is currently trading at $10.69, below its 200-day SMA of $16.92, indicating a downtrend. The 20-day and 50-day SMAs are $9.50 and $9.52, respectively, suggesting potential near-term support levels. The ATR of $0.52 reflects moderate volatility. Fundamentally, the companys forward P/E of 20.58 indicates expectations for future earnings growth, though the current P/S ratio of 0.39 suggests undervaluation relative to its revenue. With a market cap of $1.008 billion and a P/B ratio of 1.01, EVH is positioned as a mid-sized player in the health care technology sector. However, the negative ROE of -6.15% highlights ongoing profitability challenges that could impact future valuations.